In Depth 28 Jun 2024 Going nuclear: radiopharmaceuticals funding sees surge in 2024 Emerging as a new class of drugs, radiopharmaceuticals are all the rage in cancer treatment research as biotechs nab major funding deals. June 28, 2024 - 6 minutesmins - By Roohi Mariam Peter Share WhatsApp Twitter Linkedin Email
In Depth 27 Jun 2024 CRISPR-Cas13: how does the technology compare to its famous Cas9 cousin? Discover more about CRISPR-Cas13, including how it differs from CRISPR-Cas9 and what the technology can be used for. June 27, 2024 - 7 minutesmins - By Willow Shah-Neville Share WhatsApp Twitter Linkedin Email
In Depth 27 Jun 2024 The 2024 drug approval list: Eight new treatments you should know about In this article, we take a look at eight much-anticipated drugs that have been approved by regulators so far this year. June 27, 2024 - 9 minutesmins - By Roohi Mariam Peter Share WhatsApp Twitter Linkedin Email
In Depth 26 Jun 2024 Biotech megadeals: Exploring the surge in $100M+ deals Biotech and healtcare contributed to more than one out of three megadeals in 2024, find out the reasons behind it. June 26, 2024 - 9 minutesmins - By Jules Adam Share WhatsApp Twitter Linkedin Email
In Depth 24 Jun 2024 Troublesome acquisitions: when biotech M&A goes wrong Dive deeper into the world of M&A, as we take a look at some of the most prominent failed acquisitions of the last decade. June 24, 2024 - 7 minutesmins - By Willow Shah-Neville Share WhatsApp Twitter Linkedin Email
In Depth 19 Jun 2024 MASH candidates make a splash after first drug approval The first drug to treat MASH, a potentially life-threatening liver disease, was approved this year. More recent advancements bring hope to patients. June 19, 2024 - 9 minutesmins - By Roohi Mariam Peter Share WhatsApp Twitter Linkedin Email
In Depth 17 Jun 2024 Moving with the times: biopharma royalty deals on the rise A spate of royalty deals are changing the way certain biotechs press ahead. This trend seems to be an alternative to traditional biopharma fundraising. June 17, 2024 - 9 minutesmins - By Roohi Mariam Peter Share WhatsApp Twitter Linkedin Email
In Depth 10 Jun 2024 ASCO 2024: The latest advances in oncology clinical trials Biotechs from all over the country as well as other parts of the world showcased recent pipeline advancements in oncology clinical trials at ASCO 2024. June 10, 2024 - 11 minutesmins - By Roohi Mariam Peter Share WhatsApp Twitter Linkedin Email
In Depth 6 Jun 2024 CRISPR: A promising path to treating blindness Rigorous research, which has been going on for more than a decade now, suggests that CRISPR could treat genetic diseases including blindness. June 6, 2024 - 7 minutesmins - By Roohi Mariam Peter Share WhatsApp Twitter Linkedin Email
In Depth 5 Jun 2024 Evolving standards of care: new treatments for cervical cancer New treatments for cervical cancer aim to broaden therapeutic options, and improve current standards of care for patients. June 5, 2024 - 7 minutesmins - By Roohi Mariam Peter Share WhatsApp Twitter Linkedin Email
In Depth 3 Jun 2024 The biggest private biotech investments in May 2024 The companies Uniquity Bio, AltruBio, and BridgeBio Oncology Therapeutics bagged the biggest private biotech investments in May 2024. June 3, 2024 - 2 minutesmins - By Willow Shah-Neville Share WhatsApp Twitter Linkedin Email
In Depth 30 May 2024 Covalent biologics: a new class of drugs on the horizon The field of covalent biologics has made headway recently, as the only biotech in the space has bagged $100 million to move its pipeline to the clinic. May 30, 2024 - 6 minutesmins - By Roohi Mariam Peter Share WhatsApp Twitter Linkedin Email